BiotechTV - News Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
May 6, 2025
Emmanuel Savioz, Chairman & CEO of Tigen Pharma, dives into the revolutionary world of decentralized CAR-T manufacturing. He outlines how producing therapies closer to treatment sites enhances patient care. The discussion includes a cutting-edge armored-CAR program with Memorial Sloan Kettering, showcasing Tigen's innovative non-viral platform for combating blood cancers like NHL and multiple myeloma. Savioz emphasizes automation and AI's role in streamlining production, positioning Tigen at the forefront of an evolving pharmaceutical landscape.
AI Snips
Chapters
Transcript
Episode notes
Decentralized Manufacturing Benefits
- Decentralized manufacturing involves producing cell therapies near or within hospitals to improve process control.
- This method aims to industrialize therapies early in clinical trials for smoother scalability.
Why Near-Patient Manufacturing Matters
- Manufacturing CAR-T therapies near treatment sites lowers cost and supply chain risks significantly.
- Using fresh cells and lower aseptic requirements cuts cost-of-goods and capital expenses drastically.
Scalable CAR-T Manufacturing Model
- Initial decentralized manufacturing suits small Phase 1 trials but can scale for commercial production serving regional hospitals.
- Facilities can grow from 20 patients to thousands by adapting location and technology transfer.